Page last updated: 2024-08-23

daunorubicin and azelastine

daunorubicin has been researched along with azelastine in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Katoh, M; Nakajima, M; Yamazaki, H; Yokoi, T	1

Other Studies

2 other study(ies) available for daunorubicin and azelastine

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2001, Volume: 12, Issue:4 Topics: Amiodarone; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Daunorubicin; Digoxin; Enzyme Inhibitors; GABA Modulators; Gonadal Steroid Hormones; Humans; LLC-PK1 Cells; Midazolam; Mixed Function Oxygenases; Nifedipine; Phthalazines; Swine; Testosterone	2001

Article

Year

Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.

Current drug discovery technologies, 2004, Volume: 1, Issue:4

Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004

Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2001, Volume: 12, Issue:4

Topics: Amiodarone; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Daunorubicin; Digoxin; Enzyme Inhibitors; GABA Modulators; Gonadal Steroid Hormones; Humans; LLC-PK1 Cells; Midazolam; Mixed Function Oxygenases; Nifedipine; Phthalazines; Swine; Testosterone

2001